Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Dec 9

PMID 38067311

Authors

Vikneswary Ravi Kumar

Nirmala Chandralega Kampan

Nor Haslinda Abd Aziz

Chew Kah Teik

Mohamad Nasir Shafiee

P Susthitha Menon

Affiliations

Soon will be listed here.

Abstract

Epithelial Ovarian Cancer (EOC) is a leading cause of cancer-related deaths among women, mainly due to a lack of early detection and screening methods. Advanced immunoassay techniques, such as Luminex and proximity extension assay (PEA) technology, show promise in improving EOC detection by utilizing highly sensitive and specific multiplex panels to detect multiple combinations of biomarkers. However, these advanced immunoassay techniques have certain limitations, especially in validating the performance characteristics such as specificity, sensitivity, limit of detection (LOD), and dynamic range for each EOC biomarker within the panel. Implementing multiplexing in point-of-care (POC) biosensors can enhance EOC biomarker detection, with Surface Plasmon Resonance (SPR) being a versatile option among optical biosensors. There is no study on multiplex SPR biosensors specifically tailored for diagnosing EOC. Recent studies have shown promising results in the single detection of EOC biomarkers using SPR, with LOD for cancer antigen 125 (CA125) at 0.01 U/mL and human epididymis protein 4 (HE4) at 1pM. This study proposes a potential roadmap for scientists and engineers in academia and industry to develop a cost effective yet highly efficient SPR biosensor platform for detecting EOC.

Citing Articles

Exploring the Interaction of Biotinylated FcGamma RI and IgG1 Monoclonal Antibodies on Streptavidin-Coated Plasmonic Sensor Chips for Label-Free VEGF Detection.

Khaligh S, Khalid-Salako F, Kurt H, Yuce M Biosensors (Basel). 2024; 14(12).

PMID: 39727899 PMC: 11674972. DOI: 10.3390/bios14120634.

Recent advances in surface plasmon resonance for the detection of ovarian cancer biomarkers: a thorough review.

Shahbazlou S, Vandghanooni S, Dabirmanesh B, Eskandani M, Hasannia S Mikrochim Acta. 2024; 191(11):659.

PMID: 39382786 DOI: 10.1007/s00604-024-06740-3.

References

Chen F, Shen J, Wang J, Cai P, Huang Y . Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 2018; 10:1313-1318. PMC: 5968799. DOI: 10.2147/CMAR.S155693. View

Wang Q, Feng X, Liu X, Zhu S . Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis. Front Oncol. 2022; 12:868061. PMC: 9022002. DOI: 10.3389/fonc.2022.868061. View

Leandersson P, Akesson A, Hedenfalk I, Malander S, Borgfeldt C . A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. PLoS One. 2020; 15(10):e0240418. PMC: 7571712. DOI: 10.1371/journal.pone.0240418. View

Wang X, Hou T, Lin H, Lv W, Li H, Li F . In situ template generation of silver nanoparticles as amplification tags for ultrasensitive surface plasmon resonance biosensing of microRNA. Biosens Bioelectron. 2019; 137:82-87. DOI: 10.1016/j.bios.2019.05.006. View

Singh A, Gupta S, Sachan M . Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. Front Cell Dev Biol. 2019; 7:182. PMC: 6761254. DOI: 10.3389/fcell.2019.00182. View

Yi R, Zhang Z, Liu C, Qi Z . Gold-silver alloy film based surface plasmon resonance sensor for biomarker detection. Mater Sci Eng C Mater Biol Appl. 2020; 116:111126. DOI: 10.1016/j.msec.2020.111126. View

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5):672-705. DOI: 10.1093/annonc/mdz062. View

Zhang L, Chen Y, Wang K . Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2018; 43(2):135-144. DOI: 10.1016/j.currproblcancer.2018.06.001. View

Justino C, Duarte A, Rocha-Santos T . Critical overview on the application of sensors and biosensors for clinical analysis. Trends Analyt Chem. 2020; 85:36-60. PMC: 7112812. DOI: 10.1016/j.trac.2016.04.004. View

10.

Hossain K, Escobar Bermeo J, Warton K, Valenzuela S . New Approaches and Biomarker Candidates for the Early Detection of Ovarian Cancer. Front Bioeng Biotechnol. 2022; 10:819183. PMC: 8867026. DOI: 10.3389/fbioe.2022.819183. View

11.

Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen S, Ekman D . Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014; 9(4):e95192. PMC: 3995906. DOI: 10.1371/journal.pone.0095192. View

12.

Platchek M, Lu Q, Tran H, Xie W . Comparative Analysis of Multiple Immunoassays for Cytokine Profiling in Drug Discovery. SLAS Discov. 2020; 25(10):1197-1213. DOI: 10.1177/2472555220954389. View

13.

Trinidad C, Tetlow A, Bantis L, Godwin A . Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers. Cancer Prev Res (Phila). 2020; 13(3):241-252. PMC: 7080297. DOI: 10.1158/1940-6207.CAPR-19-0184. View

14.

Meyer S, Le Ru E, Etchegoin P . Combining surface plasmon resonance (SPR) spectroscopy with surface-enhanced Raman scattering (SERS). Anal Chem. 2011; 83(6):2337-44. DOI: 10.1021/ac103273r. View

15.

Said F, Menon P, Rajendran V, Shaari S, Majlis B . Investigation of graphene-on-metal substrates for SPR-based sensor using finite-difference time domain. IET Nanobiotechnol. 2017; 11(8):981-986. PMC: 8676608. DOI: 10.1049/iet-nbt.2017.0051. View

16.

Furrer D, Gregoire J, Turcotte S, Plante M, Bachvarov D, Trudel D . Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer. PLoS One. 2019; 14(6):e0218621. PMC: 6586345. DOI: 10.1371/journal.pone.0218621. View

17.

Skubitz A, Boylan K, Geschwind K, Cao Q, Starr T, Geller M . Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. Cancer Prev Res (Phila). 2019; 12(3):171-184. PMC: 6410372. DOI: 10.1158/1940-6207.CAPR-18-0221. View

18.

Ahn K, Kim H, McCoy M, Gee S, Hammock B . Immunoassays and biosensors for monitoring environmental and human exposure to pyrethroid insecticides. J Agric Food Chem. 2010; 59(7):2792-802. PMC: 3070843. DOI: 10.1021/jf1033569. View

19.

Lycke M, Kristjansdottir B, Sundfeldt K . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1):159-165. DOI: 10.1016/j.ygyno.2018.08.025. View

20.

Liu B, Martins T, Peterson L, Hill H . Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review. Cytokine. 2021; 142:155478. PMC: 7901304. DOI: 10.1016/j.cyto.2021.155478. View